Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMPEOTCMKTS:GWHPOTCMKTS:NRXGQOTCMKTS:OPTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.00$0.00$0.00▼$0.45$3K3.9435 shs8 shsGWHPGlobal WholeHealth Partners$0.00$0.00▼$0.00$10KN/AN/AN/ANRXGQNephroGenex$0.00$0.00▼$0.21$36KN/A26,223 shs2,000 shsOPTIOptec International$0.00+33.3%$0.00$0.00▼$0.00$28KN/A987,408 shs1.95 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%0.00%+275.00%+400.00%-98.80%GWHPGlobal WholeHealth Partners0.00%0.00%0.00%0.00%0.00%NRXGQNephroGenex0.00%0.00%0.00%0.00%0.00%OPTIOptec International+33.33%+41.18%+33.33%-20.00%+41.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AGWHPGlobal WholeHealth PartnersN/AN/AN/AN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AN/AN/AN/AOPTIOptec InternationalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPEAmpio Pharmaceuticals 0.00N/AN/AN/AGWHPGlobal WholeHealth Partners 0.00N/AN/AN/ANRXGQNephroGenex 0.00N/AN/AN/AOPTIOptec International 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/AGWHPGlobal WholeHealth Partners$10K0.00N/AN/AN/ANaNNRXGQNephroGenexN/AN/AN/AN/AN/AN/AOPTIOptec InternationalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/A∞N/AN/AN/AN/AN/AGWHPGlobal WholeHealth Partners-$5.16MN/A0.00N/AN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/A0.00N/AN/AN/AN/AN/AN/AOPTIOptec InternationalN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AGWHPGlobal WholeHealth PartnersN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AOPTIOptec InternationalN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPEAmpio Pharmaceuticals5.73%GWHPGlobal WholeHealth PartnersN/ANRXGQNephroGenexN/AOPTIOptec InternationalN/AInsider OwnershipCompanyInsider OwnershipAMPEAmpio Pharmaceuticals3.30%GWHPGlobal WholeHealth Partners10.30%NRXGQNephroGenexN/AOPTIOptec International50.34%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataGWHPGlobal WholeHealth Partners6143.88 million129.07 millionNot OptionableNRXGQNephroGenex1,70012.95 millionN/ANot OptionableOPTIOptec International111.65 millionN/ANot OptionableGWHP, NRXGQ, OPTI, and AMPE HeadlinesRecent News About These CompaniesOptec International Inc.May 23, 2025 | barrons.comOptec Technology Ltd.April 29, 2025 | optics.orgNew Optec CEO Updates ShareholdersJanuary 16, 2025 | globenewswire.comNew Optec CEO Updates ShareholdersJanuary 16, 2025 | prismmediawire.comGlobal Optical Current Transformer Market Size Forecasted to Surpass USD 353.0 Million Valuation by 2033, Surging at 8.4% CAGRNovember 14, 2024 | fmiblog.comSITC International Expands Fleet with New Vessel OrdersOctober 30, 2024 | markets.businessinsider.comAston University researcher develops new optical technique that could revolutionise medical diagnosticsOctober 25, 2024 | eurekalert.orgbit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming TechnologyOctober 16, 2024 | standard-journal.comOptical illusion psychology test: What you see first reveals if you are optimist or too cautious in lifeOctober 4, 2024 | timesofindia.indiatimes.comOpti Digital Welcomes Guillem Fiter as Chief Marketing OfficerSeptember 17, 2024 | exchangewire.comOGP exhibiting exciting lineup of metrology systems at IMTS 2024September 6, 2024 | insights.globalspec.comAndersen Global Enters Japan with the Collaborating Firm OptiAugust 30, 2024 | tmcnet.comThe Optical Women’s Association Announces Global Connection Event at Silmo ParisAugust 29, 2024 | invisionmag.comOptical Communication and Networking Equipment Market to Reach $54.0 Billion, Globally, by 2032 at 8.7% CAGR: Allied Market ResearchAugust 20, 2024 | tmcnet.comEngineers bring efficient optical neural networks into focusAugust 15, 2024 | sciencedaily.comOptical navigation tech could streamline planetary explorationAugust 7, 2024 | msn.comIso-propagation vortices: optical multiplexing for unprecedented information capacityMay 18, 2024 | eurekalert.orgIDTechEx Release New Global Optical & Radio Frequency Metamaterials Market ReportMay 13, 2024 | tmcnet.comGlobal Optical Coherence Tomography IndustryMay 6, 2024 | fmiblog.comZeroTech Optics Appoints Lead for International SalesMay 3, 2024 | sgbonline.comNew MarketBeat Followers Over TimeTop HeadlinesView All HeadlinesD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsTesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedBy Sam Quirke | April 30, 2025View Tesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedCrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodBy Chris Markoch | May 20, 2025View CrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?Here's Why Call Option Traders Love Dutch Bros Stock By Gabriel Osorio-Mazilli | May 12, 2025View Here's Why Call Option Traders Love Dutch Bros Stock GWHP, NRXGQ, OPTI, and AMPE Company DescriptionsAmpio Pharmaceuticals NYSE:AMPE$0.0030 0.00 (0.00%) As of 05/27/2025Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Global WholeHealth Partners OTCMKTS:GWHPGlobal WholeHealth Partners Corporation develops and markets various in-vitro diagnostic (IVD) test kits in the United States. The company offers approximately 125 diagnostic tests kits for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, yellow fever, and other epidemic and vector-borne diseases. The company was incorporated in 2013 and is based in Newport Beach, California.NephroGenex OTCMKTS:NRXGQNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.Optec International OTCMKTS:OPTI$0.0024 +0.00 (+33.33%) As of 05/28/2025 12:47 PM EasternOptec International, Inc. engages in selling and marketing optimized fuel maximizer units in North America and internationally. It markets optimized fuel maximizer for passenger vehicles, intermediate/medium duty trucks, off-road equipment, generator systems, heavy duty diesel on-road vehicles, and transportation refrigeration units. The company was formerly known as Green Meadow Products, Inc. and changed its name to Optec International, Inc. in August 2017. Optec International, Inc. was founded in 2012 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
